BSL01

BSL01 is a small molecule drug developed by Retinset SL, currently in Phase 1 clinical development. It is being investigated primarily for the treatment of diabetic retinopathy, an eye disease associated with diabetes that can lead to vision loss. The drug's therapeutic areas also include cardiovascular diseases and endocrinology/metabolic diseases, but its main active indication is diabetic retinopathy. Specific details about its mechanism of action or molecular target have not been disclosed publicly as of the latest available information[1][9]. Retinset has positioned BSL01 as a novel approach for early intervention in diabetic retinopathy, potentially offering a non-invasive treatment option[2].